Nirsevimab Reduces Risk for Severe RSV in AI/AN Children
16 hours ago · Use of nirsevimab was associated with an approximately 80% reduction in illness due to respiratory syncytial virus (RSV) infections among American Indian and Alaskan Native (AI/AN) infants, based ...
Nirsevimab Shows 76% Effectiveness in Preventing RSV in Infants
2 days ago · A new study published in Pediatrics has found that nirsevimab, a monoclonal antibody, is 76% effective in preventing medically attended respiratory syncytial virus (RSV)-related lower respiratory tract infections (LRTIs) in infants. Conducted across primary care settings in Spain during the 2023–2024 RSV season, the study provides strong evidence for nirsevimab's real-world effectiveness ...
Studies show more promising results for RSV drug nirsevimab
5 hours ago · RSV detections lower in treatment group. Rates of RSV detections were significantly lower in the treatment group compared to controls. There were 24 cases of RSV infection through day 151 in the nirsevimab arm and 54 in the placebo arm, the authors wrote. Of note, 7 (30.4%) and 16 (33.3%), respectively, were co-infections with RSV and another ...
Notes from the Field: Rollout of Nirsevimab to Protect...
1 day ago · NYC IIS data reflect administration of approximately 15,500 nirsevimab doses shortly before or during the 2023–24 RSV season, indicating that many infants and children aged 0–19 months were protected from severe RSV with this highly effective new RSV immunization (5). Approximately one half of nearly 14,000 nirsevimab doses reported to the ...
Spanish study shows 76% efficacy of nirsevimab against RSV
2 days ago · The main outcome was medically attended lower respiratory tract infection (LRTI) caused by RSV. Catch-up reduces load in primary care offices . Overall, 141 infants (88%) received nirsevimab, with 29 (21% of the sample) administered in-hospital during the RSV season, and 112 (79%) through the catch-up program, the authors said.
Studies Examine Cost-Effectiveness of Maternal RSV Vaccination ...
11 hours ago · In a second study, Hutton and colleagues simulated health care utilization and deaths from RSV with and without nirsevimab among infants aged 0 to 7 months and aged 8 to 19 months during a single ...
FDA Approves New Drug to Prevent RSV in Babies and Toddlers
Today, the U.S. Food and Drug Administration approved Beyfortus (nirsevimab-alip) for the prevention of Respiratory Syncytial Virus (RSV) lower respiratory tract disease in neonates and infants...
CDC study shows effectiveness of RSV immunization for infants
Mar 7, 2024 · New data released today in CDC’s MMWR show that nirsevimab, a long-acting monoclonal antibody product, was highly effective in protecting infants from hospitalizations associated with respiratory syncytial virus (RSV).
Health Alert Network (HAN) - 00499 | Limited Availability of Nirsevimab …
Oct 23, 2023 · For infants aged 8–19 months at increased risk of severe RSV disease entering their second season, the recommended dose is 200mg. Nirsevimab is supplied in single-dose prefilled syringes of either 50mg or 100mg. Cost of a nirsevimab prefilled syringe is the same for a 50mg dose or a 100mg dose.
RSV: Jab for winter virus could cut baby hospitalisations by 80
Dec 27, 2023 · Hospital admissions from a winter virus could be reduced by more than 80% if babies are given a single dose of a new antibody treatment, a study says. Respiratory syncytial virus (RSV)...